Previous 10 | Next 10 |
A Zebrafish embryo at an early stage of development ( Jeffrey Farrell, Schier Lab /Harvard University) Investment Thesis 10x Genomics ( TXG ) is leading the cell revolution hailed by the prestigious Science Magazine as the “breakthrough of the year“ in 2018. The market is i...
10x Genomics (NASDAQ: TXG ) announces the commercial launch of its Chromium Single Cell Immune Profiling v2 product that, it says, extends the capabilities of the first version and is used by researchers to understand COVID-19 to advance science for the development of vaccines, antiviral...
PLEASANTON, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) strengthened the research toolkit of scientists around the globe today with the launch of its Chromium Single Cell Immune Profiling v2 product. The new product extends the capabilities of the...
PLEASANTON, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the second quarter 2020 after market close on Tuesday, August 11, 2020. The company’s management will webcast a corresponding conference call beginnin...
PLEASANTON, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- 10x Genomics , Inc. (Nasdaq: TXG) today unveiled the first 45 members selected for participation in its Visium Clinical Translational Research Network (CTRN). Members selected are focused on research in oncology, immuno-oncology, neur...
PLEASANTON, Calif., May 20, 2020 (GLOBE NEWSWIRE) -- Building on its earlier reveal at the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics , Inc. (Nasdaq: TXG) today launched its Targeted Gene Expression Solution for single cell and shortly following for sp...
SAN FRANCISCO and PLEASANTON, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Today, 10x Genomics (Nasdaq: TXG) and One Medical (Nasdaq: ONEM) announced the two organizations are partnering to pioneer a path toward the safe return to work by deploying a comprehensive approach to COVID-19 t...
10x Genomics, Inc. (TXG) Q1 2020 Results Conference Call May 11, 2020 04:30 PM ET Company Participants Carrie Mendivil - Investor Relations Serge Saxonov - Co-Founder & Chief Executive Officer Justin McAnear - Chief Financial Officer Brad Crutchfield - Chief Commercial Offi...
Image source: The Motley Fool. 10x Genomics Inc (NASDAQ: TXG) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
10x Genomics (NASDAQ: TXG ): Q1 GAAP EPS of -$0.22 misses by $0.09 . More news on: 10x Genomics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 06:00:09 ET Kyle Mikson from Canaccord Genuity issued a price target of $32.00 for TXG on 2024-07-23 05:09:00. The adjusted price target was set to $32.00. At the time of the announcement, TXG was trading at $18.11. The overall price target consensus is at $24...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024 PR Newswire PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report fi...
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...